A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India

Sponsor
Novo Nordisk A/S
Study ID
NCT05502562
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Oral semaglutide — DRUG
    Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.

Study Details

The purpose of the study is to look at the change in blood sugar levels in participants with type 2 diabetes who start using oral semaglutide. Participants will get oral semaglutide as prescribed to them by the study doctor. The study will last for about 8-11 months (34-44 weeks). Participants will be asked to complete a questionnaire about how they take oral semaglutide tablets. Participants will complete this questionnaire during the normal scheduled visit with the doctor and will be asked questions about their health and their diabetes treatment and lab tests as part of their normal doctor's appointment.

Key Dates

Start date
Feb 24, 2023
Status verified
Sep 2024
Primary completion
Jun 3, 2024
Completion
Jun 3, 2024

Study Design

Enrollment
388 participants (actual)

Arms

  • Arm: Participants with type 2 diabetes
    Adult participants with type 2 diabetes and naive to injectable glucose-lowering treatment.

Primary Outcome Measure

Change in Glycated haemoglobin A1c (HbA1c) [ Time Frame: From baseline (week 0) to End of Study visit (V3) (week 34-44) ]

Related Studies